0001209191-20-038189.txt : 20200622 0001209191-20-038189.hdr.sgml : 20200622 20200622162948 ACCESSION NUMBER: 0001209191-20-038189 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200618 FILED AS OF DATE: 20200622 DATE AS OF CHANGE: 20200622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wenqing Yao CENTRAL INDEX KEY: 0001624033 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 20979154 MAIL ADDRESS: STREET 1: ROUTE 141 AND HENRY CLAY ROAD CITY: WILMINGTON STATE: DE ZIP: 19880 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-18 0 0000879169 INCYTE CORP INCY 0001624033 Wenqing Yao 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 EVP, Head of Discovery Chem Common Stock 2020-06-18 4 A 0 25000 0.00 A 152188 D Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on June 18, 2020. The performance shares will vest in full on June 28, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date. Each performance share initially represented the right to receive one share of common stock based on, and subject to, the approval of a new chemical entity developed by the issuer as a drug by the U.S. FDA or the European Medicines Agency during a specified performance period. Includes an aggregate of 95,832 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units and performance shares that have not vested as of June 18, 2020. /s/ Wenqing Yao 2020-06-22